PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2535800-7	1989	The Ca2+ channel blocker verapamil (100 microM) significantly inhibited the GRF response to both forskolin and phorbol 12-myristate 13-acetate.	Tetradecanoylphorbol Acetate	111-142	growth hormone releasing hormone	Rattus norvegicus	76-79	
1678698-6	1991	Potentiation by phorbol 12-myristate 13-acetate of forskolin-stimulated GHRH and SS release was observed.	Tetradecanoylphorbol Acetate	16-47	growth hormone releasing hormone	Rattus norvegicus	72-76	
8734475-5	1996	Prolonged exposure to TPA reduced the subsequent GH response to TPA equally in neonates and adults, but differentially affected the GH response to GHRH; TPA exposure reduced the GH response to GHRH in neonates, but not in adults.	Tetradecanoylphorbol Acetate	22-25	growth hormone releasing hormone	Rattus norvegicus	147-151	
7649093-11	1995	The effect of GHRH on GHF-1 mRNA levels could be mimicked by direct activators of second messenger signaling systems such as forskolin (10(-5) M) or the phorbol ester tumor promoter tetradecanoyl phorbol acetate (TPA) (10(-6) M).	Tetradecanoylphorbol Acetate	213-216	growth hormone releasing hormone	Rattus norvegicus	14-18	
2535800-6	1989	In nonpretreated cultures, forskolin (1-100 microM) and the protein kinase C activator phorbol 12-myristate 13-acetate (10 nM-1 microM), stimulated basal GRF release in a dose-dependent fashion.	Tetradecanoylphorbol Acetate	87-118	growth hormone releasing hormone	Rattus norvegicus	154-157	
3141549-2	1988	Pretreatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 3 h significantly suppressed the rGH release induced by GRF, but not that by 8-bromo-cAMP 20 h later; this suppressive effect of TPA was concentration-dependent from 8 to 160 nmol/l, and complete suppression was observed after pretreatment with 80-160 nmol TPA/l.	Tetradecanoylphorbol Acetate	18-54	growth hormone releasing hormone	Rattus norvegicus	121-124	
3141549-2	1988	Pretreatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 3 h significantly suppressed the rGH release induced by GRF, but not that by 8-bromo-cAMP 20 h later; this suppressive effect of TPA was concentration-dependent from 8 to 160 nmol/l, and complete suppression was observed after pretreatment with 80-160 nmol TPA/l.	Tetradecanoylphorbol Acetate	56-59	growth hormone releasing hormone	Rattus norvegicus	121-124	
3141549-3	1988	Production of cAMP by pituitary cells stimulated with GRF was similarly attenuated in TPA-pretreated cells.	Tetradecanoylphorbol Acetate	86-89	growth hormone releasing hormone	Rattus norvegicus	54-57	
3141549-4	1988	The rGH responsiveness to GRF of these cells was fully recovered on prolonged culture (40 h), suggesting that the inhibitory effect of TPA is reversible.	Tetradecanoylphorbol Acetate	135-138	growth hormone releasing hormone	Rattus norvegicus	26-29	
3141549-5	1988	In contrast, pretreatment with GRF (5 nmol/l) resulted in suppression of the rGH response to subsequent exposure to GRF (5 nmol/l) or 8-bromo-cAMP (10 mmol/l), but not to TPA.	Tetradecanoylphorbol Acetate	171-174	growth hormone releasing hormone	Rattus norvegicus	31-34	
3141549-5	1988	In contrast, pretreatment with GRF (5 nmol/l) resulted in suppression of the rGH response to subsequent exposure to GRF (5 nmol/l) or 8-bromo-cAMP (10 mmol/l), but not to TPA.	Tetradecanoylphorbol Acetate	171-174	growth hormone releasing hormone	Rattus norvegicus	116-119	
3141549-6	1988	These observations suggest that pretreatment with TPA modifies the rGH response to GRF at steps before the formation of cAMP.	Tetradecanoylphorbol Acetate	50-53	growth hormone releasing hormone	Rattus norvegicus	83-86	
2896538-6	1987	Incubation in a low calcium medium that totally blocks GRF-stimulated GH release also inhibits TPA-stimulated GH release.	Tetradecanoylphorbol Acetate	95-98	growth hormone releasing hormone	Rattus norvegicus	55-58